A dual conditional CRISPR-Cas9 system to activate gene editing and reduce off-target effects in human stem cells.
CRISPR-Cas9
MT: RNA/DNA editing
conditional CRISPR-Cas9
gene editing
human stem cell
off-target effect
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
14 Jun 2022
14 Jun 2022
Historique:
received:
12
09
2021
accepted:
22
04
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
27
5
2022
Statut:
epublish
Résumé
The CRISPR-Cas9 system has emerged as a powerful and efficient tool for genome editing. An important drawback of the CRISPR-Cas9 system is the constitutive endonuclease activity when Cas9 endonuclease and its sgRNA are co-expressed. This constitutive activity results in undesirable off-target effects that hinder studies using the system, such as probing gene functions or its therapeutic use in humans. Here, we describe a convenient method that allows temporal and tight control of CRISPR-Cas9 activity by combining transcriptional regulation of Cas9 expression and protein stability control of Cas9 in human stem cells. To achieve this dual control, we combined the doxycycline-inducible system for transcriptional regulation and FKBP12-derived destabilizing domain fused to Cas9 for protein stability regulation. We showed that approximately 5%-10% of Cas9 expression was observed when only one of the two controls was applied. By combining two systems, we markedly lowered the baseline Cas9 expression and limited the exposure time of Cas9 endonuclease in the cell, resulting in little or no undesirable on- or off-target effects. We anticipate that this dual conditional CRISPR-Cas9 system can serve as a valuable tool for systematic characterization and identification of genes for various pathological processes.
Identifiants
pubmed: 35615005
doi: 10.1016/j.omtn.2022.04.013
pii: S2162-2531(22)00089-0
pmc: PMC9112054
doi:
Types de publication
Journal Article
Langues
eng
Pagination
656-669Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Sci Rep. 2015 Jun 11;5:11315
pubmed: 26066060
Microbiology (Reading). 2005 Aug;151(Pt 8):2551-2561
pubmed: 16079334
Nature. 2015 Oct 1;526(7571):55-61
pubmed: 26432244
Nat Biotechnol. 2015 Feb;33(2):187-197
pubmed: 25513782
Nat Biotechnol. 2014 Apr;32(4):347-55
pubmed: 24584096
Mol Ther. 2012 May;20(5):1014-21
pubmed: 22434137
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10437-42
pubmed: 26216948
Stem Cells. 2007 Oct;25(10):2559-66
pubmed: 17628023
Nat Biotechnol. 2013 Mar;31(3):230-2
pubmed: 23360966
Genome Res. 2014 Jan;24(1):132-41
pubmed: 24253446
Nat Biotechnol. 2013 Sep;31(9):822-6
pubmed: 23792628
Nat Commun. 2017 Feb 22;8:14370
pubmed: 28224990
Nat Biotechnol. 2016 Aug;34(8):863-8
pubmed: 27272384
Nat Biotechnol. 2016 Jun;34(6):646-51
pubmed: 27136077
Nature. 2016 Jan 28;529(7587):490-5
pubmed: 26735016
Nat Methods. 2015 Apr;12(4):326-8
pubmed: 25730490
Nat Biotechnol. 2016 Aug;34(8):869-74
pubmed: 27347757
Hum Gene Ther. 2005 Nov;16(11):1241-6
pubmed: 16259557
Nat Med. 2018 Aug;24(8):1216-1224
pubmed: 30082871
Invest Ophthalmol Vis Sci. 2014 Jun 12;55(7):4119-27
pubmed: 24925877
Genome Res. 2014 Jun;24(6):1012-9
pubmed: 24696461
Nat Biotechnol. 2015 Jul;33(7):755-60
pubmed: 26076431
Science. 2007 Mar 23;315(5819):1709-12
pubmed: 17379808
Curr Gene Ther. 2016;16(3):156-67
pubmed: 27216914
Cell. 2006 Sep 8;126(5):995-1004
pubmed: 16959577
Metab Eng. 2016 Sep;37:11-23
pubmed: 27040671
Sci Rep. 2015 Jul 30;5:12524
pubmed: 26224331
Stem Cells Dev. 2012 Jan 20;21(2):191-205
pubmed: 21699412
Nucleic Acids Res. 2015 Jul 27;43(13):6450-8
pubmed: 26082496
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Sci Rep. 2018 Aug 3;8(1):11649
pubmed: 30076383
Comput Struct Biotechnol J. 2019 Jul 30;17:1171-1177
pubmed: 31462973
Nucleic Acids Res. 2016 Nov 2;44(19):e149
pubmed: 27458201
J Virol. 2000 Nov;74(22):10778-84
pubmed: 11044122
J Mol Evol. 2005 Feb;60(2):174-82
pubmed: 15791728
Acta Pharm Sin B. 2021 Aug;11(8):2150-2171
pubmed: 34522582
Nat Biotechnol. 2022 Jan;40(1):94-102
pubmed: 34475560
Nat Biotechnol. 2014 Mar;32(3):279-284
pubmed: 24463574
Mol Cell Biol. 2000 Oct;20(20):7419-26
pubmed: 11003639
J Clin Invest. 2014 Nov;124(11):4953-64
pubmed: 25295540
Science. 2013 Feb 15;339(6121):823-6
pubmed: 23287722
Nat Biotechnol. 2015 Apr;33(4):390-394
pubmed: 25690852
Stem Cell Res. 2016 May;16(3):640-50
pubmed: 27062358
BMC Biotechnol. 2010 Nov 24;10:81
pubmed: 21106052
Nat Biotechnol. 2013 Sep;31(9):833-8
pubmed: 23907171
Nat Methods. 2015 Mar;12(3):237-43, 1 p following 243
pubmed: 25664545
Cell Stem Cell. 2014 Aug 7;15(2):215-226
pubmed: 24931489